Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
2,357,266
-
Shares change
-
+1,171,778
-
Total reported value, excl. options
-
$136,154,624
-
Value change
-
+$67,642,279
-
Put/Call ratio
-
143%
-
Number of buys
-
16
-
Number of sells
-
-21
-
Price
-
$57.76
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q3 2017
53 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q3 2017.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,357,266 shares
.
Largest 10 shareholders include BANK OF AMERICA CORP /DE/ (1,222,367 shares), GOLDMAN SACHS GROUP INC (350,935 shares), CITIGROUP INC (200,335 shares), UBS Group AG (120,869 shares), SG Americas Securities, LLC (103,642 shares), RAYMOND JAMES & ASSOCIATES (88,515 shares), MORGAN STANLEY (70,194 shares), CLS Investments, LLC (22,000 shares), Psagot Investment House Ltd. (21,895 shares), and CITADEL ADVISORS LLC (18,510 shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.